ストックスクリーナーアプリを入手
23.94
1.44%
0.34
Viking Therapeutics Inc (VKTX) 最新ニュース
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735 - Yahoo Finance
H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data - Yahoo Finance
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide - Yahoo Finance
Viking Therapeutics (VKTX) Gains Attention with Promising Diabetes Treatment | LLY Stock News - GuruFocus
2 Stocks Down by 25% or More This Year to Buy and Hold - Yahoo Finance
Viking Therapeutics: A Lot More Compelling After The MeltdownInitiating Cautious Buy (Rating Upgrade) - Seeking Alpha
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Viking Therapeutics (VKTX) to Announce Q1 2025 Financial Results - GuruFocus
Viking Therapeutics Inc (VKTX) Stock Price, Trades & News - GuruFocus
Viking Therapeutics (VKTX) Shares Decline Following Eli Lilly's Phase 3 Results | LLY Stock News - GuruFocus
Viking Therapeutics slips after Eli Lilly reports orforglipron trial results - TipRanks
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Quantisnow
Viking Therapeutics to Report Financial Results for First Quarte - GuruFocus
Viking Therapeutics Sets Q1 Earnings Date: Key Updates Expected on Metabolic Drug Pipeline - Stock Titan
Viking Therapeutics Stock Pops But Struggles to Hold Gains - MarketBeat
Viking Therapeutics Stock Pops But Struggles To Hold Gains - Barchart.com
Viking Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VKTX - Benzinga
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market - Seeking Alpha
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? - MSN
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Zacks Investment Research
Viking Therapeutics (VKTX) Surges as Pfizer Halts Obesity Drug - GuruFocus
Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? - MSN
Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4) - Quantisnow
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg.com
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Globe and Mail
Pfizer's $130B Weight-Loss Dream Just Collapsed - Yahoo Finance
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? - Benzinga
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug - Schaeffer's Investment Research
Viking Therapeutics shares surge on Pfizer’s drug discontinuation By Investing.com - Investing.com India
Viking Therapeutics shares surge on Pfizer’s drug discontinuation - Investing.com
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years? - Yahoo
Viking Therapeutics stock hits 52-week low at $20.26 - Investing.com Australia
Viking Therapeutics stock hits 52-week low at $20.26 By Investing.com - Investing.com South Africa
Goldman Sachs Initiates Coverage of Viking Therapeutics (VKTX) with Neutral Recommendation - Nasdaq
Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4) - Quantisnow
Goldman Sachs Initiates Coverage on Viking Therapeutics (VKTX) w - GuruFocus
Viking Therapeutics draws Neutral rating at Goldman Sachs on competitive headwinds - Seeking Alpha
Goldman initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target - MarketScreener
Goldman Sachs sets Viking Therapeutics stock at Neutral By Investing.com - Investing.com Canada
The Smartest Biotech Stocks to Buy With $50 - AOL.com
When the Price of (VKTX) Talks, People Listen - news.stocktradersdaily.com
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow
Viking therapeutics director Rouan buys $29,942 in stock By Investing.com - Investing.com Canada
Viking therapeutics director Rouan buys $29,942 in stock - Investing.com India
Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4) - Quantisnow
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now? - Yahoo Finance
2.51%
大文字化:
|
ボリューム (24 時間):